[Application of β-cyclodextrin in the formulation of ODT tablets containing ibuprofen].
BACKGROUND
Oral disintegrating tablet (ODT) dissolves or disintegrates in saliva and then it is swallowed. Diluent in direct compression formulation has a dual role: it increases bulk of the dosage form and it promotes binding of the constituent particles of the formulation. Hence, selection of diluent is important in tablets produced by direct compression method.


OBJECTIVE
The aim of this work was to exame feasibility of preparing and optimizing oral disintegrating tablet formulation using β-cyclodextrin as a diluent.


METHODS
400 mg round tablets were prepared by direct compression method on single punch tablet press using flat plain-face. 60% β-CD and MCC (microcrystalline cellulose - MCC-Vivapur 102) were used at different proportions for all the formulations. 5% of Kollidon CL was added as superdisintegrant. The eight formulations prepared were assessed for weight variation, thickness, disintegration time, hardness and dissolution rate according to FP IX. A dissolution test was performed at 37ºC using the paddle method at 50 rpm with 900 mL phosphate buffer (pH 6.8) as a dissolution medium.


RESULTS
The content of ibuprofen sodium was found inside the ± 5% of the theoretical value. Hardness values of presented tablets were in the range 0.11-0.15 kG/mm2. Friability of the tablets lower than 1% indicates that the developed formulations can be processed and handled without excessive care. Disintegration time was in the range of 86 to 161 s.


CONCLUSIONS
The results confirm the good mechanical properties of tablets containing β-CD. A composition with 20% β-CD and 40% MCC fulfilled a maximum requisite of an optimum formulation. These properties were similar to Ludiflash, the formulation used for comparison purposes. In the present study, higher concentration of β cyclodextrin was found to improve the hardness of tablets without increasing the disintegration time.
Katedra i Zakład Farmacji Stosowanej, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Łukasz
Ł
Zimmer
Katedra i Zakład Farmacji Stosowanej, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Regina
R
Kasperek
Katedra i Zakład Farmacji Stosowanej, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Ewa
E
Poleszak
D000284:Administration, Oral; D002482:Cellulose / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D005079:Excipients / Q000737:chemistry; D005240:Feasibility Studies; D006244:Hardness; D012995:Solubility; D013607:Tablets / Q000737:chemistry*; D047392:beta-Cyclodextrins / Q000008:administration & dosage* / Q000737:chemistry*
D005079:Excipients; D013607:Tablets; D047392:beta-Cyclodextrins; C477445:vivapur; D002482:Cellulose; C031215:betadex; C109691:microcrystalline cellulose